Recent Company News

• 09:18 AM ET Nov 03, 2025
  

  Capricor Therapeutics publishes peer-reviewed study in Biomedicines of its investigational cell therapy, Deramiocel ($6.51, 0.00)

• 01:02 AM ET Nov 03, 2025
  

  Genentech's Gazyva announces Phase III ALLEGORY study of of Gazyva (obinutuzumab) met its primary endpoint (CHF 258.90, 0.00)

• 02:05 AM ET Oct 28, 2025
  

  Roche's Genentech announces Phase III INShore study of Gazyva (obinutuzumab) met its primary endpoint (CHF 267.40, 0.00)

• 01:02 AM ET Oct 20, 2025
  

  FDA approves Genentech's Gazyva to treat LN (CHF 283.70, 0.00)

• 06:29 AM ET Oct 17, 2025
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Roche Holding's Gazyvaro (CHF 280.70, -4.60)

• 01:04 AM ET Oct 14, 2025
  

  UCB announces final analysis of OLE study of Fintepla in Lennox-Gastaut syndrome published in Epilepsy and Behavior (€260.00, 0.00)

• 02:33 AM ET Sep 30, 2025
  

  Vicore Pharma Holding announces Japan's Ministry of Health, Labor and Welfare has granted Orphan Drug designation to buloxibutid for the treatment of idiopathic pulmonary fibrosis (SEK 13.00, 0.00)

• 07:18 AM ET Sep 25, 2025
  

  Capricor Therapeutics provides regulatory update on Deramiocel program for Duchenne muscular dystrophy following Type A meeting ($6.19, 0.00)

• 03:27 AM ET Sep 19, 2025
  

  Japan approves Nippon Shinyaku's JAYPIRCA for lymphocytic leukemia (¥3342.0000, 0)

• 02:41 AM ET Sep 19, 2025
  

  FDA grants orphan drug designation to Nippon Shinyaku's NS-051/NCNP-04 for treatment of Duchenne Muscular Dystrophy (¥3342.0000, 0)